Tipps:

Forum: Aktien Ausland

CVM $ CEL-Sci $ Next Hotstock on Watch $

Verfasst am: 25.04.2017 - 22:31 Uhr von Maier | Gelesen: 316  |  Beiträge: 0

Maier
Maier am 25.04.2017 - 22:31 Uhr - Maier ignorieren | Maier eine BM schreiben
Beitrag: #1

Diesen Kommentar: Melden | Kommentar schreiben
CVM $  CEL-Sci $  Next Hotstock on Watch $
https://investorshub.advfn.com/boards/board.aspx?board_id=61
Cel-Sci Corporation (CVM)
http://www.cel-sci.com/
CEL-SCI Scientist Presents at the World Vaccine Congress











Print



Alert








Cel Sci (AMEX:CVM)
Historical Stock Chart
1 Month : From Mar 2017 to Apr 2017
" target="_blank" title=" Bild "> Bild

CEL-SCI Corporation (NYSE MKT: CVM ) today announced that Dr. Daniel Zimmerman, its Senior Vice President
of Research, Cellular Immunology, is presenting at the 17th
Annual World Vaccine Congress held in Washington D.C. on April 12, 2017.
The conference runs from April 10-12, 2017. The title of his
presentation is “ Unmet need for therapeutic vaccines for autoimmune
conditions with emphasis on arthritis – and a look into the future.



At the conference, Dr. Zimmerman is presenting data supporting a
potentially novel approach to fighting the inflammation in the joints
caused by rheumatoid arthritis. He introduced animal data that
demonstrates that using CEL-SCI’s LEAPS CEL-4000 Rheumatoid Arthritis
treatment vaccine downregulates pro-inflammatory T-cell responses and
upregulates anti-inflammatory T-cell responses. This finding was
confirmed by an examination of cytokines in the serum of the animals and
by earlier data on CEL-4000 and CEL-2000 in the two animal models
examined. Information on other autoimmune conditions showing either a
Th1 or Th17 signature cytokine profile was cited and supportive as well.


Dr. Zimmerman said, “I believe based on the above findings and
observations of others that the future of this novel approach using
LEAPS therapeutic vaccines could be expanded to other autoimmune
conditions with similar Th1 and Th17 signature cytokine phenotypes
including multiple sclerosis, autoimmune uveitis, and type I diabetes.”


About the World Vaccine Congress


The World Vaccine Congress is now well-established as the must
attend
global vaccine event each year, where leaders of the industry come
to
discuss science and do business. Now in its 17th year, the event
in 2017
will bring over 700 senior vaccine executives to learn, meet and
form
partnerships. - See more at:
http://www.terrapinn.com/conference/world-vaccine-congress-washington/our-Story.stm#sthash.Cjiak553.dpuf


About LEAPS


L.E.A.P.S. (Ligand Epitope Antigen Presentation System) is a CEL-SCI
patented platform technology designed to stimulate antigen-specific
immune responses in T-cells using synthetic peptides. LEAPS constructs
physically link the antigenic peptide with a T-cell binding ligand and
are delivered directly to the recipient immune system by injection or
mucosal absorption, potentially enhancing T-cell responses to a
particular antigen.


About CEL-SCI


CEL-SCI's work is focused on finding the best way to activate the immune
system to fight cancer and infectious diseases. The Company has
operations in Vienna, Virginia, and in/near Baltimore, Maryland.


Forward-Looking Statements


This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. When
used in this press release, the words "intends," "believes,"
"anticipated," "plans" and "expects," and similar expressions, are
intended to identify forward-looking statements. Such statements are
subject to risks and uncertainties that could cause actual results to
differ materially from those projected. Factors that could cause or
contribute to such differences include, an inability to duplicate the
clinical results demonstrated in clinical studies, timely development of
any potential products that can be shown to be safe and effective,
receiving necessary regulatory approvals, difficulties in manufacturing
any of the Company's potential products, inability to raise the
necessary capital and the risk factors set forth from time to time in
CEL-SCI's filings with the Securities and Exchange Commission, including
but not limited to its report on Form 10-K and 10-K/A for the year ended
September 30, 2016. The Company undertakes no obligation to publicly
release the result of any revision to these forward-looking statements
which may be made to reflect the events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.



Bild
View source version on businesswire.com: http://www.businesswire.com/news/home/20170412005106/en/
CEL-SCI Corporation
Gavin de Windt, 703-506-9460
www.cel-sci.com









Latest CVM Messages